Genaissance Pharmaceuticals, Inc. announced that it has entered into an agreement with Ferring Pharmaceuticals under which Genaissance will provide certain pharmacogenomic services and technology to Ferring.

Genaissance will provide to Ferring pharmacogenomic expertise including GLP-compliant DNA banking services through its Morrisville, NC, operations. Genaissance will also collaborate with Ferring to identify clinical projects for the application of Genaissance's HAP Technology.

"We are pleased to be working with Ferring. They hold a global leadership position in key therapeutic areas, making us extremely pleased to have been chosen by them to provide pharmacogenomics technology and services," said Kevin Rakin, president and CEO of Genaissance Pharmaceuticals. "This agreement also expands our own global positioning, progressing our entry into serving the European pharmaceutical industry."

Ferring Pharmaceuticals, founded in 1950, is a research-driven specialty biopharmaceutical group active in global markets. The group identifies, develops and markets innovative products in the fields of urology, gynecology, gastroenterology and endocrinology. Ferring operates in more than 40 countries.

Genaissance Pharmaceuticals, Inc. discovers and uses human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and pharmacogenomic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance is headquartered in Science Park in New Haven, Connecticut.